Search - tctmd.com

Displaying 81 - 94 of 94

Sort: Relevancy | Date

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

Michael O'Riordan

July 10, 2017

News Daily News

Betrixaban Approved for Prevention of VTE

Michael O'Riordan

June 23, 2017

News Daily News

FDA Expands Sapien 3 Indication to Aortic, Mitral Valve-in-Valve Replacement

Michael O'Riordan

June 06, 2017

News Daily News

Rapid Rule-Out Strategy With High-Sensitivity Troponin Shows Promise Ahead of US Commercial Availability of Test

L.A. McKeown

April 17, 2017

News Daily News

FDA Approves Next-Gen CoreValve Evolut PRO Valve

Todd Neale

March 22, 2017

News Daily News

First High-Sensitivity Troponin Assay Finally Comes to the United States

Todd Neale

January 24, 2017

News Daily News

FDA Approves Amplatzer PFO Occluder for Prevention of Recurrent Stroke

Yael L. Maxwell

October 28, 2016

News Daily News

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

Yael L. Maxwell

August 24, 2016

News Daily News

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Michael O'Riordan

August 18, 2016

News Daily News

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

Michael O'Riordan

July 05, 2016

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

News Daily News

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

Advertisement

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

Betrixaban Approved for Prevention of VTE

FDA Expands Sapien 3 Indication to Aortic, Mitral Valve-in-Valve Replacement

Rapid Rule-Out Strategy With High-Sensitivity Troponin Shows Promise Ahead of US Commercial Availability of Test

FDA Approves Next-Gen CoreValve Evolut PRO Valve

First High-Sensitivity Troponin Assay Finally Comes to the United States

FDA Approves Amplatzer PFO Occluder for Prevention of Recurrent Stroke

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content